Chancity

Past eventHeld October 20–22, 2026

Annual Covalent Drug Discovery & Development Summit 2026

A covalent drug discovery and development event for biotech and pharma leaders, billed as featuring data-driven case studies and translational strategies.

Hampton Inn Boston Seaport District, Boston, MA

Held
October 20–22, 2026
Venue
Hampton Inn Boston Seaport District, Boston, MA
Attendance
80+ covalent-focused attendees

TL;DR

  • The summit took place October 20–22, 2026, at Hampton Inn Boston Seaport District in Boston, MA.
  • The organizer billed the event as drawing 80+ covalent-focused attendees.

Source: covalent-drug-discovery.com/about-event

About

The summit was billed as uniting experts from Bristol Myers Squibb, Novartis, Pfizer, Biogen, Nexo Therapeutics, and Frontier Medicines for data-driven case studies and translational strategies. Hanson Wade Group organized the event.

Source: covalent-drug-discovery.com/venue-accommodation

Who was in the room

Biotech and pharma leaders

Covalent drug discovery and development leaders from biotech and pharma were the intended audience.

Featured speakers

4 listed

Doug Johnson

Senior Principal Scientist · Bristol Myers Squibb

Chris Haggard

Co-Founder & Chief Technical Officer · Axiom Therapeutics

Dean Stamos

Co-Founder & Chief Scientific Officer · Expedition Medicines

Jaimeen Devraj

Associate Research Fellow · Pfizer

Venue & travel

Venue

Hampton Inn Boston Seaport District

Questions people ask

6 answered

Annual Covalent Drug Discovery & Development Summit 2026 took place October 20–22, 2026.

The organizer reported 80+ covalent-focused attendees.

It was held at Hampton Inn Boston Seaport District in Boston, MA.

Covalent drug discovery and development leaders from biotech and pharma were the intended audience. The organizer named experts from Bristol Myers Squibb, Novartis, Pfizer, Biogen, Nexo Therapeutics, and Frontier Medicines.

It was most useful for medicinal chemists and drug discovery leads working on covalent inhibitors, since the roughly 80 attendees were billed as all covalent-focused and speakers were scheduled from Bristol Myers Squibb, Novartis, Pfizer, Biogen and Frontier Medicines, with data-driven case studies. The small size made it good for candid scientific exchange, but the door price of $4,397 was steep for academics or teams outside covalent work, who would have gotten less than those directly developing covalent programs.

Attendees at biotech and pharma scientific meetings usually wear business casual, such as slacks and a collared shirt or sweater, with few suits. Boston in late October is cool and often damp, so a jacket was practical.

Related events

Find more events with this kind of reach.

We score 300,000+ B2B events by decision-maker density, so you can find the next one for your ICP.

Also listed in